Skip to Main Content
  1. Home
  2. SEER Data & Software
  3. SEER Incidence Database
  4. Specialized Databases
  5. Available Databases
  6. Invasive Breast Cancer with Oncotype DX Recurrence Score

Invasive Breast Cancer with Oncotype DX Recurrence Score

* indicates required field

Access the Database

To request access this specialized database, you must already have access to the latest SEER Reasearch Plus Data.

  • If you do not have access to SEER Research Plus Data, first request Access to the SEER data.
  • If you already have access, use the request options below.

Required Information:

  • Contact Information
  • SEER*Stat Username
  • Purpose and Analysis Plan

Submit a Request

This database is available only to U.S. based researchers affiliated with U.S. institutions.

These databases include Oncotype DX Breast Recurrence Score (RS)-related variables for invasive breast cancer cases. The variables were obtained through a linkage of all invasive breast cancer cases diagnosed from 2004 to 2019 in the SEER registries to Oncotype DX Breast RS test orders and results provided by Exact Sciences (formerly provided by Genomic Health). Alaska Native Tumor Registry did not participate in the linkage. Details about the linkage methods can be found in a recent journal article (1).

Approximately 1,629,000 invasive breast cancer cases were included in the linkage, of which 364,292 were linked to Oncotype DX RS test orders and results.

Variable Definitions

The specialized Oncotype DX RS fields are described below.

Variable Name in SEER*Stat Values Description
OncotypeDX Breast RS (2004-2019) 0-100 OncotypeDX Breast Recurrence Score (RS) reported on a scale of 0-100
OncotypeDX Breast RS reason no score linked (2004-2019)
  1. Cancelled Test - Cancelled by physician or patients before result was returned;
  2. Failed Test - Inadequate tissue sample;
  3. Outside Analysis Criteria;
  4. Non-Unique - Patient had multiple tumors

Test ordered; results may be available but not provided to registries.

  1. Test cancelled by provider or patient; results not released;
  2. Test failed due to inadequate tissue sample;
  3. ER/PR negative or HER2 positive by RT-PCR per tests by Exact Sciences;
  4. Multiple tests for the same tumor or multiple tumors
OncotypeDX Breast RS year of test report (2004-2019) 2004+ Year of test report
OncotypeDX Breast RS month of test report (2004-2019) Jan-Dec Month of test report (not available in case listing)
OncotypeDX Breast RS months since diagnosis (2004-2019)

0+

997: Unknown

998: Test before DX

 Calculated based on month and year of diagnosis and month and year of test report. Unknown occurs when month of diagnosis is unknown and year of diagnosis is not greater than test year

Database Details

There are two Oncotype DX Breast RS databases available to request, with and without Census Tract Attributes.

All databases are identical to the SEER Research Plus database other than the specialized fields described above.

  1. Oncotype DX Breast RS Database
    • This one is linked to county-level attributes, which include county-level SES, rurality, and demographics.
    • Includes all tumor records from 2000-2020 with follow-up through 2020, but the Oncotype DX RS fields are available for tested patients diagnosed from 2004 to 2019.
    • There are 3 datasets available:
      1. 17 Registries (excl AK) – includes 187,608 tumors linked to test results
      2. 22 Registries (excl AK) Limited-Field – includes 343,392 tumors linked to test results
        • Not available in Survival sessions
      3. 22 Registries (excl AK, IL and MA) Limited-Field – includes 293,668 tumors linked to test results
  2. Oncotype DX Breast RS with Census Tract Attributes Database
    • There are no geographic identifiers included in this database due to confidentiality concerns.
    • Includes all tumor records from 2006-2020 with follow-up through 2020, but the Oncotype DX RS fields are available for tested patients diagnosed from 2004 to 2019.
    • There are 2 datasets available:
      1. 17 Registries (excl AK) – includes 185,351 tumors linked to test results
      2. 22 Registries (excl AK, IL and MA) – includes 290,558 tumors linked to test results
    • For detailed information about census tract-level SES and rurality variables, refer to Census Tract-level SES and Rurality Database.

The databases that include SEER 22 registries (excluding AK) contain two additional SEER variables that are available in SEER17 SEER Research Plus but not in SEER22 Research Plus limited fields databases.

  1. Regional nodes examined (1988+)
  2. Regional nodes positive (1988+)

Data Limitations and Analytical Considerations

The SEER treatment data is limited to the first course of treatment, therefore it does not have the full sequence of treatments (refer to the Treatment Data Limitations for more information).

Reference

  1. Petkov VI, Byun JS, Ward KC, Schussler NC, Archer NP, Bentler S, Doherty JA, Durbin EB, Gershman ST, Cheng I, Insaf T, Gonsalves L, Hernandez BY, Koch L, Liu L, Monnereau A, Morawski BM, Schwartz SM, Stroup A, Wiggins C, Wu XC, Bonds S, Negoita S, Penberthy L. Reporting tumor genomic test results to SEER registries via linkages. J Natl Cancer Inst Monogr. 2024 Aug 1;2024(65):168-179. [PubMed Abstract]